Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACHIEVE LIFE SCIENCES, INC.ACHV · Entity 5072 | Director · CEO and President | April 18, 2026 | April 21, 2026 |
| Tarsus Pharmaceuticals, Inc.TARS · Entity 1836 | Director | June 25, 2026 | June 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACHIEVE LIFE SCIENCES, INC.
Report date April 18, 2026 · Filed April 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security · Expires 2036-04-18 | Direct | 1,800,965 |
Reported balance
After 2026-04-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-18 · Grant · Acquired 1,800,965 · Balance 1,800,965 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock at settlement. F2: Pursuant to the terms of the award agreement governing the RSU, the number of shares underlying the RSU vest as to 1/4 of the total award on the one-year anniversary of April 18, 2026, and thereafter in substantially equal quarterly installments on the twelve quarterly anniversaries thereafter, subject to the Reporting Person's provision of services to the Issuer on each vesting date. The RSUs are eligible for accelerated vesting pursuant to the Reporting Person's employment agreement with the Issuer. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.25 · Expires 2036-04-18 | Direct | 3,601,929 |
Reported balance
After 2026-04-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-18 · Grant · Acquired 3,601,929 · Balance 3,601,929 F3: The option will vest as to 1/4 of the total award on the one-year anniversary of April 18, 2026, and thereafter in substantially equal monthly installments over thirty-six months, subject to the Reporting Person's provision of services to the Issuer on each vesting date. The shares subject to the option are eligible for accelerated vesting pursuant to the Reporting Person's employment agreement with the Issuer. |
| Performance Restricted Stock Unit (PRSU)SEC Table II · derivative / convertible security · Expires 2036-04-18 | Direct | 11,706,270 |
Reported balance
After 2026-04-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-18 · Grant · Acquired 11,706,270 · Balance 11,706,270 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock at settlement. F4: Pursuant to the terms of the award agreement governing the PRSU, the number of shares underlying the PRSU vest based on achievement of eight share price milestones ranging from 2x to 9x of a reference price, in whole or in part, upon achievement of certain financial performance conditions. The PRSUs are eligible for accelerated vesting pursuant to the Reporting Person's employment agreement with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock at settlement.
F2: Pursuant to the terms of the award agreement governing the RSU, the number of shares underlying the RSU vest as to 1/4 of the total award on the one-year anniversary of April 18, 2026, and thereafter in substantially equal quarterly installments on the twelve quarterly anniversaries thereafter, subject to the Reporting Person's provision of services to the Issuer on each vesting date. The RSUs are eligible for accelerated vesting pursuant to the Reporting Person's employment agreement with the Issuer.
F3: The option will vest as to 1/4 of the total award on the one-year anniversary of April 18, 2026, and thereafter in substantially equal monthly installments over thirty-six months, subject to the Reporting Person's provision of services to the Issuer on each vesting date. The shares subject to the option are eligible for accelerated vesting pursuant to the Reporting Person's employment agreement with the Issuer.
F4: Pursuant to the terms of the award agreement governing the PRSU, the number of shares underlying the PRSU vest based on achievement of eight share price milestones ranging from 2x to 9x of a reference price, in whole or in part, upon achievement of certain financial performance conditions. The PRSUs are eligible for accelerated vesting pursuant to the Reporting Person's employment agreement with the Issuer.
Tarsus Pharmaceuticals, Inc.
Report date June 25, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.34 · Expires 2036-06-24 | Direct | 3,837 |
Reported balance
After 2026-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-25 · Grant · Acquired 3,837 · Balance 3,837 F1: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,417 |
Reported balance
After 2026-06-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-25 · Grant · Acquired 2,417 · Balance 2,417 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
F3: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2026 Filed Jun 29, 2026 20:31 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 2,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001827722-26-000004 · wk-form4_1782765110.xml · derivative · entry 2 Goldberg Andrew D. · CIK 0001827722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,417 Underlying: Common Stock · 2,417 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F3 · derivative.expiration_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 20:31 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 3,837 | $0.00 Strike: $64.34 | $0.00 |
DisclosureSEC source: 0001827722-26-000004 · wk-form4_1782765110.xml · derivative · entry 1 Goldberg Andrew D. · CIK 0001827722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,837 Underlying: Common Stock · 3,837 shares Expires 2036-06-24 F1 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 20:05 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 2,954 | $0.00 | $0.00 |
DisclosureSEC source: 0001827722-26-000002 · wk-form4_1781640318.xml · derivative · entry 2 Goldberg Andrew D. · CIK 0001827722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,954 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: RSUs granted on June 12, 2025, in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F3 · derivative.expiration_date: RSUs granted on June 12, 2025, in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 20:05 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 2,954 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001827722-26-000002 · wk-form4_1781640318.xml · nonDerivative · entry 1 Goldberg Andrew D. · CIK 0001827722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| April 18, 2026 Filed Apr 21, 2026 22:20 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantPerformance Restricted Stock Unit (PRSU) · Derivative | 11,706,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-167418 · ownership.xml · derivative · entry 3 Goldberg Andrew D. · CIK 0001827722 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,706,270 Underlying: Common Stock · 11,706,270 shares Expires 2036-04-18 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock at settlement. F4 · derivative.exercise_date: Pursuant to the terms of the award agreement governing the PRSU, the number of shares underlying the PRSU vest based on achievement of eight share price milestones ranging from 2x to 9x of a reference price, in whole or in part, upon achievement of certain financial performance conditions. The PRSUs are eligible for accelerated vesting pursuant to the Reporting Person's employment agreement with the Issuer. Read SEC document |
| April 18, 2026 Filed Apr 21, 2026 22:20 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 3,601,929 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001193125-26-167418 · ownership.xml · derivative · entry 2 Goldberg Andrew D. · CIK 0001827722 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,601,929 Underlying: Common Stock · 3,601,929 shares Expires 2036-04-18 F3 · derivative.exercise_date: The option will vest as to 1/4 of the total award on the one-year anniversary of April 18, 2026, and thereafter in substantially equal monthly installments over thirty-six months, subject to the Reporting Person's provision of services to the Issuer on each vesting date. The shares subject to the option are eligible for accelerated vesting pursuant to the Reporting Person's employment agreement with the Issuer. Read SEC document |
| April 18, 2026 Filed Apr 21, 2026 22:20 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantRestricted Stock Unit (RSU) · Derivative | 1,800,965 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-167418 · ownership.xml · derivative · entry 1 Goldberg Andrew D. · CIK 0001827722 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,800,965 Underlying: Common Stock · 1,800,965 shares Expires 2036-04-18 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock at settlement. F2 · derivative.exercise_date: Pursuant to the terms of the award agreement governing the RSU, the number of shares underlying the RSU vest as to 1/4 of the total award on the one-year anniversary of April 18, 2026, and thereafter in substantially equal quarterly installments on the twelve quarterly anniversaries thereafter, subject to the Reporting Person's provision of services to the Issuer on each vesting date. The RSUs are eligible for accelerated vesting pursuant to the Reporting Person's employment agreement with the Issuer. Read SEC document |
| June 13, 2025 Filed Jun 16, 2025 20:04 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 3,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-25-000092 · wk-form4_1750104285.xml · derivative · entry 4 Goldberg Andrew D. · CIK 0001827722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,350 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F5 · derivative.exercise_date: RSUs granted on June 13, 2024, in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F5 · derivative.expiration_date: RSUs granted on June 13, 2024, in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 13, 2025 Filed Jun 16, 2025 20:04 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 3,350 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001819790-25-000092 · wk-form4_1750104285.xml · nonDerivative · entry 1 Goldberg Andrew D. · CIK 0001827722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:04 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 2,954 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-25-000092 · wk-form4_1750104285.xml · derivative · entry 3 Goldberg Andrew D. · CIK 0001827722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,954 Underlying: Common Stock · 2,954 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F4 · derivative.exercise_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F4 · derivative.expiration_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:04 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 4,540 | $0.00 Strike: $40.95 | $0.00 |
DisclosureSEC source: 0001819790-25-000092 · wk-form4_1750104285.xml · derivative · entry 2 Goldberg Andrew D. · CIK 0001827722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,540 Underlying: Common Stock · 4,540 shares Expires 2035-06-11 F2 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 20:01 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionStock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $12.89 | $0.00 |
DisclosureSEC source: 0001819790-25-000030 · wk-form4_1741723288.xml · derivative · entry 2 Goldberg Andrew D. · CIK 0001827722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2032-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2021 annual meeting of stockholders. The option vested in full on the one-year anniversary of the date of grant. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 20:01 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 7,000 | $12.89 | $90,230.00 |
DisclosureSEC source: 0001819790-25-000030 · wk-form4_1741723288.xml · nonDerivative · entry 1 Goldberg Andrew D. · CIK 0001827722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2024 Filed Jun 25, 2024 22:26 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 3,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-24-000103 · wk-form4_1719354372.xml · derivative · entry 2 Goldberg Andrew D. · CIK 0001827722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,350 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: RSUs granted on June 22, 2023, in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F3 · derivative.expiration_date: RSUs granted on June 22, 2023, in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 24, 2024 Filed Jun 25, 2024 22:26 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 3,350 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001819790-24-000103 · wk-form4_1719354372.xml · nonDerivative · entry 1 Goldberg Andrew D. · CIK 0001827722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 21:45 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 3,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-24-000085 · wk-form4_1718401530.xml · derivative · entry 2 Goldberg Andrew D. · CIK 0001827722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,350 Underlying: Common Stock · 3,350 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F3 · derivative.expiration_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 21:45 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $33.14 | $0.00 |
DisclosureSEC source: 0001819790-24-000085 · wk-form4_1718401530.xml · derivative · entry 1 Goldberg Andrew D. · CIK 0001827722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2034-06-12 F1 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 23:30 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | PurchaseCommon Stock | 1,000 | $18.96 | $18,960.00 |
DisclosureSEC source: 0001827722-23-000002 · wk-form4_1703028650.xml · nonDerivative · entry 1 Goldberg Andrew D. · CIK 0001827722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 21:56 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 3,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-23-000058 · wk-form4_1687816565.xml · derivative · entry 2 Goldberg Andrew D. · CIK 0001827722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,350 Underlying: Common Stock · 3,350 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: RSUs granted on June 22, 2023, in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F3 · derivative.expiration_date: RSUs granted on June 22, 2023, in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 21:56 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $17.99 | $0.00 |
DisclosureSEC source: 0001819790-23-000058 · wk-form4_1687816565.xml · derivative · entry 1 Goldberg Andrew D. · CIK 0001827722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 22:18 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-23-000043 · wk-form4_1687385913.xml · derivative · entry 2 Goldberg Andrew D. · CIK 0001827722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: RSUs granted on June 16, 2022, in connection with the Reporting Person's service as a non-employee director as of the Company's 2022 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F3 · derivative.expiration_date: RSUs granted on June 16, 2022, in connection with the Reporting Person's service as a non-employee director as of the Company's 2022 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 22:18 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 2,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001819790-23-000043 · wk-form4_1687385913.xml · nonDerivative · entry 1 Goldberg Andrew D. · CIK 0001827722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| June 16, 2022 Filed Jul 1, 2022 16:21 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-018342 · wf-form4_165669246081797.xml · derivative · entry 2 Goldberg Andrew D. · CIK 0001827722 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2022 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F3 · derivative.expiration_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2022 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 16, 2022 Filed Jul 1, 2022 16:21 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $12.89 | $0.00 |
DisclosureSEC source: 0001628280-22-018342 · wf-form4_165669246081797.xml · derivative · entry 1 Goldberg Andrew D. · CIK 0001827722 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2022 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 23:21 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $35.26 | $0.00 |
DisclosureSEC source: 0001209191-21-041705 · doc4.xml · derivative · entry 2 Goldberg Andrew D. · CIK 0001827722 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-15 F2 · derivative.exercise_date: Option granted in connection with the Reporting Person's service as a non-employee director as of the closing of the Company's initial public offering and continued service as of the Company's 2021 annual meeting of stockholders. The option is fully vested. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 23:21 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $35.26 | $0.00 |
DisclosureSEC source: 0001209191-21-041705 · doc4.xml · derivative · entry 1 Goldberg Andrew D. · CIK 0001827722 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2031-06-15 F1 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2021 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.